The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.
Phase I
9534: A Phase I Trial of Ibrutinib Plus PD 0332991 (Palbociclib) in Patients with Previously Treated Mantle Cell Lymphoma. Weill Medical College of Cornell University; Martin, Peter. (646) 962-2064
9540: A Phase 1 Study of Lenalidomide and Ibrutinib in Combination with Rituximab in Relapsed and Refractory CLL and SLL. MedStar Georgetown University Hospital; Ujjani, Chaitra S. (202) 444-1212
9552: A Phase 1 Study of MLN0128 and Bevacizumab in Patients with Recurrent Glioblastoma and Other Solid Tumors. Dana-Farber Cancer Institute; Nayak, Lakshmi. (617) 632-2166
9557: Phase I Study of AT13387 in Combination with Dabrafenib and Trametinib in BRAF-Inhibitor Resistant Patients with BRAF-Mutant Melanoma. Dana-Farber Cancer Institute; Sullivan, Ryan Joseph. (617) 724-4000
9585: Phase I Study of MLN0128 (NSC# 768435) in Combination with Ziv-Aflibercept (NSC# 724770) in Patients with Advanced Cancers. MD Anderson Cancer Center; Naing, Aung. (713) 563-0181
9762: Phase I Trial of the Combination of Bortezomib and Clofarabine in Adults with Refractory Solid Tumors. National Cancer Institute Developmental Therapeutics Clinic; Kummar, Shivaani. (301) 435-0517
AMC-090: A Phase 1/Pharmacokinetic Study of Erlotinib for Advanced Non-Small Cell Lung Cancer in Persons with HIV Infection. AIDS-Associated Malignancies Clinical Trials Consortium; Haigentz, Missak. (718) 920-4826
NRG-BR001: A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases. NRG Oncology; Chmura, Steven J. (773) 702-7319
Phase II
9446: A Phase 2 Study of Trametinib in Combination with Radioiodine (RAI) for RAS Mutant or RAS/RAF Wild-Type, RAI-Refractory Recurrent and/or Metastatic Thyroid Cancers. Memorial Sloan Kettering Cancer Center; Ho, Alan Loh. (646) 888-4235
A091305: A Phase 2 Randomized Study of Efatutazone, an Oral PPAR Agonist, In Combination with Paclitaxel Versus Paclitaxel in Patients with Advanced Anaplastic Thyroid Cancer. Alliance for Clinical Trials in Oncology; Smallridge, Robert C. (904) 953-2392
Other Phases
A151221: Serum Androgens as Prognostic of Survival in Metastatic Castration Resistant Prostate Cancer. Alliance for Clinical Trials in Oncology; Ryan, Charles James. (415) 514-6380
AALL14B6-Q: Molecular Profiling to Impact the Management of Pre-B ALL: A Pilot Study. Children’s Oncology Group; McGowan-Jordan, Jean. (613) 737-7600 X 2276
ANBL14B1-Q: Assessment of Fucsosyl-GM1 in High Risk Pediatric Neuroblastoma. Children’s Oncology Group; Maris, John M. (215) 590-5244
EL613T1: Significance of IFN-alpha Adjuvant Therapy Treatment and Clinical Outcomes on BRAF V600E Mutation Vs. Wild Type Melanoma Patients in Correlation with Immunoscore Assessment. ECOG-ACRIN Cancer Research Group; Kirkwood, John Munn. (412) 623-7707
NRG-GU-TS001: Evaluation of MRE11 as a Biomarker in Muscle Invasive Bladder Cancer Treated with Chemoradiotherapy: A Secondary Analysis of RTOG 8802, 8903, 9506, and 9706, 9906 and 0233. NRG Oncology; Shipley, William U. (617) 726-8146
S9031-S9333-S0106-S0112-B: Identification and Development of Biomarkers Profiles to Predict Clinical Outcomes for Acute Myeloid Leukemia (AML) Patients with NPM1 pos/FLT3-ITD neg Genotype. SWOG; Stirewalt, Derek Lynn. (206) 667-5386
